Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion OLE in Severe Knee Osteoarthritis
NCT03349645Phase 3Terminated
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of aspartyl-alanyl-diketopiperazine in osteoarthritis (OA), sponsored by Ampio Pharmaceuticals, Inc.. Started Dec 2017; status: terminated.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03349645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349645.